AI-Enabled Integrated Drug Discovery and Development Platform

Neathera has established an AI-enabled, integrated antibody engineering and CMC translational platform focused on autoimmune and complement-mediated diseases. Rather than centering on a single target or standalone technology, the platform is built around real-world clinical unmet needs and integrates molecular design, engineering optimization, developability assessment, process development, and clinical translation into a closed-loop system aimed at generating development-ready, scalable therapeutics.

By combining AI-driven antibody design with Neathera’s deep expertise in antibody engineering and industrial CMC development, the platform enables key attributes—efficacy, half-life, route of administration, formulation properties, and manufacturability—to be considered and optimized early in discovery. Supported by standardized and modularized process and formulation capabilities, the platform enables rapid translation of candidates into high-concentration, subcutaneous injectable biologics, allowing progression from PCC to clinical-ready drug product within 12–14 months.

描述
Key Platform Features
  • Programs are initiated based on clearly defined clinical scenarios, including administration route, dosing frequency, safety constraints, and patient usability, ensuring outputs are clinically actionable solutions rather than research-only molecules.
    Clinical-need–driven development
    Programs are initiated based on clearly defined clinical scenarios, including administration route, dosing frequency, safety constraints, and patient usability, ensuring outputs are clinically actionable solutions rather than research-only molecules.
  • Generative AI and sequence/structure-based engineering approaches are used to design and optimize antibodies for potency, selectivity, stability, immunogenicity, and half-life at the earliest stages.
    AI-enabled antibody engineering
    Generative AI and sequence/structure-based engineering approaches are used to design and optimize antibodies for potency, selectivity, stability, immunogenicity, and half-life at the earliest stages.
  • Developability is embedded into candidate selection, with early evaluation of expression yield, aggregation risk, formulation feasibility, and scalability to proactively eliminate non-viable molecules.
    Early developability integration
    Developability is embedded into candidate selection, with early evaluation of expression yield, aggregation risk, formulation feasibility, and scalability to proactively eliminate non-viable molecules.
  • The platform supports high-expression cell line development, scalable and cost-efficient manufacturing processes, and stable high-concentration subcutaneous formulations, ensuring readiness for both clinical and commercial supply.
    Integrated CMC and formulation platform
    The platform supports high-expression cell line development, scalable and cost-efficient manufacturing processes, and stable high-concentration subcutaneous formulations, ensuring readiness for both clinical and commercial supply.
  • Clinical strategy and regulatory considerations are incorporated from project initiation, leveraging Neathera’s translational experience and clinical networks to accelerate proof-of-concept and key development milestones.
    Translation-oriented execution
    Clinical strategy and regulatory considerations are incorporated from project initiation, leveraging Neathera’s translational experience and clinical networks to accelerate proof-of-concept and key development milestones.
This platform has been validated across multiple programs, including EA5, a long-acting subcutaneous C5 inhibitor, and continues to support the generation of innovative antibody candidates with clear clinical utility and commercial feasibility. It demonstrates Neathera’s ability to systematically translate complex immunology into scalable, patient-ready therapeutics through an integrated, repeatable development engine.
Company Name：Neathera Inc.
Email：info@neathera.com
描述
CONTACT US
NAVIGATION
Copyright © 2019-2026 Neathera Inc. All rights reserved.